A 12-Month Analysis of the Dermatologic Effects and Durability of Midface Volume Correction With DEFCL Volumizing Filler in a Prospective, Single-Center Study.
Journal
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
ISSN: 1524-4725
Titre abrégé: Dermatol Surg
Pays: United States
ID NLM: 9504371
Informations de publication
Date de publication:
02 Jul 2024
02 Jul 2024
Historique:
medline:
2
7
2024
pubmed:
2
7
2024
entrez:
2
7
2024
Statut:
aheadofprint
Résumé
Certain manufacturing processes confer distinctive rheologic features to hyaluronic acid (HA), ensuring long-lasting effects. Skin quality improvement and the volumizing effects of the DEFCL volumizer filler, a sterile, biodegradable, viscoelastic, transparent, isotonic, and homogenized injectable cross-linked high G' filler for the treatment of moderate-to-severe age-related midface changes, were initially documented at 6 months after the first injection. The authors aimed to objectively evaluate the effects of the DEFCL volumizer filler in improving skin density, thickness, and biomechanical properties and on tissue volume augmentation in women with midface volume loss after 12 months. Fifty women with midface volume loss were recruited in this prospective, noncomparative, single-center, postmarket study. The authors report changes in skin density, thickness, and quality and subjective and objective evaluation of facial and/or cheek volume augmentation using the Global Aesthetic Improvement Scale, as well as injection site reactions and adverse events. Improvements in skin quality and thickness and volumization were maintained 12 months after the first injection. Injector and patient satisfaction were highly rated with only mild adverse reactions observed. Skin improvement and volumizing effects persisted in patients treated with the DEFCL volumizer after 12 months.
Sections du résumé
BACKGROUND
BACKGROUND
Certain manufacturing processes confer distinctive rheologic features to hyaluronic acid (HA), ensuring long-lasting effects. Skin quality improvement and the volumizing effects of the DEFCL volumizer filler, a sterile, biodegradable, viscoelastic, transparent, isotonic, and homogenized injectable cross-linked high G' filler for the treatment of moderate-to-severe age-related midface changes, were initially documented at 6 months after the first injection.
OBJECTIVE
OBJECTIVE
The authors aimed to objectively evaluate the effects of the DEFCL volumizer filler in improving skin density, thickness, and biomechanical properties and on tissue volume augmentation in women with midface volume loss after 12 months.
MATERIALS AND METHODS
METHODS
Fifty women with midface volume loss were recruited in this prospective, noncomparative, single-center, postmarket study. The authors report changes in skin density, thickness, and quality and subjective and objective evaluation of facial and/or cheek volume augmentation using the Global Aesthetic Improvement Scale, as well as injection site reactions and adverse events.
RESULTS
RESULTS
Improvements in skin quality and thickness and volumization were maintained 12 months after the first injection. Injector and patient satisfaction were highly rated with only mild adverse reactions observed.
CONCLUSION
CONCLUSIONS
Skin improvement and volumizing effects persisted in patients treated with the DEFCL volumizer after 12 months.
Identifiants
pubmed: 38954752
doi: 10.1097/DSS.0000000000004307
pii: 00042728-990000000-00863
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society for Dermatologic Surgery, Inc.
Références
Salti G, Siquier-Dameto G, Rharbaoui S, Hernandez Malgapo DM, et al. An interim 6-month analysis of the dermatologic effects and midface volume correction with XTR CL Filler in a prospective, single-center study. Dermatol Surg 2023;49:943–8.
Alexiades M, Palm MD, Kaufman-Janette J, Papel I, et al. A randomized, multicenter, evaluator-blind study to evaluate the safety and effectiveness of VYC-12L treatment for skin quality improvements. Dermatol Surg 2023;49:682–8.
Cavallini M, Papagni M, Ryder TJ, Patalano M. Skin quality improvement with VYC-12, a new injectable hyaluronic acid: objective results using digital analysis. Dermatol Surg 2019;45:1598–604.
Niforos F, Ogilvie P, Cavallini M, Leys C, et al. VYC-12 injectable gel is safe and effective for improvement of facial skin topography: a prospective study. Clin Cosmet Investig Dermatol 2019;12:791–8.
Peng JH, Peng PH. HA filler injection and skin quality-literature minireview and injection techniques. Indian J Plast Surg 2020;53:198–206.
Salti G, Fundarò SP. Evaluation of the rheologic and physicochemical properties of a novel hyaluronic acid filler range with eXcellent Three-Dimensional Reticulation (XTR™) Technology. Polymers (Basel) 2020;12:1644.
Sparavigna A, La Gatta A, Bellia G, La Penna L, et al. Evaluation of the volumizing performance of a new volumizer filler in volunteers with age-related midfacial volume defects. Clin Cosmet Investig Dermatol 2020;13:683–90.
Heike CL, Upson K, Stuhaug E, Weinberg SM. 3D digital stereophotogrammetry: a practical guide to facial image acquisition. Head Face Med 2010;6:18.
Alsing KK, Serup J. High-frequency ultrasound skin thickness: comparison of manual reading and automatic border detection includes assessment of interobserver variation of measurement. Skin Res Technol 2020;26:832–8.
Dobrev HP. A study of human skin mechanical properties by means of Cutometer. Folia Med (Plovdiv) 2002;44:5–10.
Nakab L, Hee CK, Guetta O. Improvements in skin quality biological markers in skin explants using hyaluronic acid filler VYC-12L. Plast Reconstr Surg Glob Open 2020;8:e2723.
Zhu J, Tang X, Jia Y, Ho CT, et al. Applications and delivery mechanisms of hyaluronic acid used for topical/transdermal delivery: a review. Int J Pharmaceutics 2020;578:119127.
Humphrey S, Manson Brown S, Cross SJ, Mehta R. Defining skin quality: clinical relevance, terminology, and assessment. Dermatol Surg 2021;47:974–81.